Who are Administration of ceralasertib monotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Praxbind, Natrecor, Monoket, CEFOTIAM, Monocid, Dtic-Dome.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/administration-of-ceralasertib-monotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Administration of ceralasertib monotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Administration of ceralasertib monotherapy (Administration of ceralasertib monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ATR inhibitor. Area: Oncology.

phase 1 ATR inhibitor ATR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Administration of ceralasertib monotherapy (Administration of ceralasertib monotherapy) — AstraZeneca. Ceralasertib is an ATP-competitive inhibitor of the serine/threonine kinase ATR, which is involved in DNA damage response pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Administration of ceralasertib monotherapy TARGET	Administration of ceralasertib monotherapy	AstraZeneca	phase 1	ATR inhibitor	ATR
Praxbind	IDARUCIZUMAB	Boehringer Ingelheim	marketed	Humanized Monoclonal Antibody Fragment [EPC]	dabigatran and its acylglucuronide metabolites	2015-01-01
Natrecor	NESIRITIDE	Scios Llc	marketed	Natriuretic Peptide	Atrial natriuretic peptide receptor 1	2001-01-01
Monoket	ISOSORBIDE MONONITRATE		marketed	Nitrate Vasodilator [EPC]	Atrial natriuretic peptide receptor 1	1991-01-01
CEFOTIAM	CEFOTIAM		marketed	cefotiam	Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein	1988-01-01
Monocid	CEFONICID		marketed	cefonicid	Matrix metalloproteinase-9	1984-01-01
Dtic-Dome	dacarbazine	Bayer	marketed	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1975-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ATR inhibitor class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Administration of ceralasertib monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/administration-of-ceralasertib-monotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab